Statins for treatment of dyslipidemia in chronic kidney disease

Area of Science:

• Nephrology
• Cardiology
• Clinical Pharmacology

Background:

• Dyslipidemia is a major cardiovascular risk factor, with specific lipid abnormalities prevalent in chronic kidney disease (CKD).
• Lipoprotein metabolism is significantly altered in non-dialysis-dependent CKD, hemodialysis (HD), and peritoneal dialysis (PD) patients, leading to a proatherogenic profile.
• Peritoneal dialysis patients exhibit more severe dyslipidemia due to glucose absorption and protein loss.

Purpose of the Study:

• To review the impact of dyslipidemia in CKD patients.
• To evaluate the efficacy and safety of statin therapy in CKD patients, particularly those on dialysis.
• To discuss current evidence and ongoing research regarding statin use in CKD.

Main Methods:

• Review of existing literature on dyslipidemia in CKD.
• Analysis of observational studies and randomized controlled trials (RCTs) on statin use in CKD patients (HD and PD).
• Consideration of ongoing RCTs (SHARP, AURORA) and clinical guidelines.

Main Results:

• Statins are effective in altering lipid profiles in dialysis-dependent CKD patients, similar to the general population.
• Observational studies indicate statin treatment is associated with a 30%-50% mortality reduction in dialysis-dependent CKD patients.
• While one RCT in diabetic HD patients did not show significant reduction in primary endpoints, ongoing trials are crucial.

Conclusions:

• Statins are well-tolerated and demonstrate potential efficacy in reducing cardiovascular mortality in CKD patients on dialysis.
• Further research, including ongoing RCTs, is needed to solidify the role of statins in CKD dyslipidemia management.
• Consideration of statin therapy for at-risk dialysis patients, especially those on PD, is warranted given their atherogenic lipid profile and current evidence.